Drug General Information |
Drug ID |
D0D9LT
|
Former ID |
DNC005044
|
Drug Name |
5-Methyl-pyrrolidin-(2Z)-ylideneamine
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C5H10N2
|
Canonical SMILES |
CC1CCC(=N1)N
|
InChI |
1S/C5H10N2/c1-4-2-3-5(6)7-4/h4H,2-3H2,1H3,(H2,6,7)
|
InChIKey |
DDQFWSHGBVMBEM-UHFFFAOYSA-N
|
PubChem Compound ID |
|
Target and Pathway |
Target(s) |
Nitric oxide synthase, inducible |
Target Info |
Inhibitor |
[1]
|
Nitric-oxide synthase, brain |
Target Info |
Inhibitor |
[1]
|
Nitric-oxide synthase, endothelial |
Target Info |
Inhibitor |
[1]
|
BioCyc Pathway
|
Citrulline-nitric oxide cyclePWY-4983:Citrulline-nitric oxide cyclePWY-4983:Citrulline-nitric oxide cycle
|
KEGG Pathway
|
Arginine biosynthesis
|
Arginine and proline metabolism
|
Metabolic pathways
|
Calcium signaling pathway
|
HIF-1 signaling pathway
|
Peroxisome
|
Salmonella infection
|
Pertussis
|
Leishmaniasis
|
Chagas disease (American trypanosomiasis)
|
Toxoplasmosis
|
Amoebiasis
|
Tuberculosis
|
Pathways in cancer
|
Small cell lung cancerhsa00330:Arginine and proline metabolism
|
Phagosome
|
Circadian entrainment
|
Long-term depression
|
Salivary secretion
|
Alzheimer's disease
|
Amyotrophic lateral sclerosis (ALS)hsa00330:Arginine and proline metabolism
|
cGMP-PKG signaling pathway
|
Sphingolipid signaling pathway
|
PI3K-Akt signaling pathway
|
VEGF signaling pathway
|
Platelet activation
|
Estrogen signaling pathway
|
Oxytocin signaling pathway
|
NetPath Pathway
|
IL1 Signaling Pathway
|
IL2 Signaling PathwayNetPath_4:EGFR1 Signaling PathwayNetPath_8:Wnt Signaling Pathway
|
PANTHER Pathway
|
CCKR signaling map STP00005:Angiogenesis
|
Endothelin signaling pathway
|
Interleukin signaling pathway
|
PI3 kinase pathway
|
VEGF signaling pathway
|
Pathway Interaction Database
|
IL12-mediated signaling events
|
Alpha9 beta1 integrin signaling events
|
ATF-2 transcription factor network
|
IL23-mediated signaling events
|
Signaling mediated by p38-alpha and p38-beta
|
HIF-1-alpha transcription factor networker_nongenomic_pathway:Plasma membrane estrogen receptor signaling
|
Validated transcriptional targets of AP1 family members Fra1 and Fra2
|
Angiopoietin receptor Tie2-mediated signaling
|
Thromboxane A2 receptor signaling
|
SHP2 signaling
|
VEGFR1 specific signals
|
Signaling events mediated by VEGFR1 and VEGFR2
|
PAR1-mediated thrombin signaling events
|
PathWhiz Pathway
|
Arginine and Proline Metabolism
|
Reactome
|
ROS production in response to bacteria
|
Nitric oxide stimulates guanylate cyclaseR-HSA-1222556:ROS production in response to bacteria
|
Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
|
eNOS activation
|
Nitric oxide stimulates guanylate cyclase
|
VEGFR2 mediated vascular permeability
|
WikiPathways
|
Type II interferon signaling (IFNG)
|
Spinal Cord Injury
|
AGE/RAGE pathway
|
Effects of Nitric OxideWP727:Monoamine Transport
|
Myometrial Relaxation and Contraction Pathways
|
Amyotrophic lateral sclerosis (ALS)
|
Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis
|
Alzheimers Disease
|
Effects of Nitric Oxide
|
Serotonin Transporter ActivityWP554:ACE Inhibitor Pathway
|
EGF/EGFR Signaling Pathway
|
JAK/STAT
|
Corticotropin-releasing hormone
|
Endothelin Pathways
|
Leptin signaling pathway
|
Metabolism of nitric oxide
|
Angiogenesis
|
References |
REF 1 | Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. |